Melasma is an acquired hyperpigmentation disorder with a multifactorial etiology and complex
pathogenesis that can significantly diminish the quality of life for affected patients. As of
now, melasma therapy remains challenging due to its high recurrence rate and the common
occurrence of treatment-related side effects. The use of depigmentation agents is a crucial
component in managing melasma. Hydroquinone stands as the first-line depigmentation agent for
melasma; however, its use often leads to adverse effects. Therefore, alternative
depigmentation agents are needed. Curcuma xanthorriza Roxb., a native plant of Indonesia,
operates by inhibiting the tyrosinase enzyme, reducing MITF transcription, and inhibiting
α-MSH. Despite these potential benefits, Curcuma xanthorriza Roxb. has not been utilized as a
depigmentation agent. Research on the effectiveness of Curcuma xanthorriza Roxb. as a
depigmentation agent in melasma treatment has not been conducted. Therefore, it is essential
to conduct research to determine the effectiveness of a 10% Curcuma xanthorrhiza Roxb. cream
in reducing MASI scores and enhancing skin brightness in epidermal-type melasma.